{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pasritamig"],["pasritamig","JNJ-87189401"]],"indication":"late-line metastatic castration-resistant prostate cancer","name":"KLK2-comPAS","nct_id":"NCT07164443","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=klk2-compas-nct07164443. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"KLK2-comPAS","arms":[{"description":"Participants in Part 1 will receive 2 step-up doses of pasritamig intravenously (IV) followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.","label":"Part 1: Pasritamig+Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"description":"Participants in Part 1 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.","label":"Part 1: Placebo+BSC","type":"PLACEBO_COMPARATOR"},{"description":"Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.","label":"Part 2: Pasritamig+BSC","type":"EXPERIMENTAL"},{"description":"Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. JNJ-87189401 will be administered with the first target dose of pasritamig. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.","label":"Part 2: Pasritamig+JNJ-87189401+BSC","type":"EXPERIMENTAL"},{"description":"Participants in Part 2 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.","label":"Part 2: Placebo +BSC","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-08-18","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostatic Neoplasms"],"enrollment":{"count":1203,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pasritamig","otherNames":["JNJ-78278343"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"OTHER"},{"name":"Best Supportive Care (BSC)","otherNames":[],"type":"DRUG"},{"name":"JNJ-87189401","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-11-03","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-08-18","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 2 years and 8 months"}],"references":[],"start_date":{"date":"2025-09-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","url":"https://clinicaltrials.gov/study/NCT07164443"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/klk2-compas-nct07164443"}